immune-mediated disease News
-
Cytovale Secures Additional BARDA Funding for 10-Minute IntelliSep Test for Sepsis
Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, has received additional funding from Biomedical Research and Development Authority (BARDA) to help advance the company’s 10-minute IntelliSep sepsis risk stratification test towards commercial launch. This latest contract action, ...
-
New Study Establishes Cytovale IntelliSep Test in the Rapid Diagnosis of Sepsis
Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune mediated diseases, today announced the publication of a study in the peer-reviewed journal PLOS ONE evaluating its IntelliSep test in the rapid diagnosis of sepsis in the hospital emergency department. Data from the study, “Development and validation of a cellular ...
-
New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis
Low dose arm of the study met the co-primary endpoints of percent change in Eczema Area and Severity Index (EASI) score from baseline, and incidence of treatment-emergent adverse events, through week 16 First trial to assess the effects of blocking OX40-Ligand, a key immune system regulator, in patients with moderate-to-severe atopic dermatitis Data support amlitelimab as a potential ...
-
Cytovale IntelliSep Test Demonstrates Potential to Rapidly Risk-Stratify Suspected COVID-19 Patients in New Study
Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, today announced a new study on its investigational IntelliSep test has been published in the peer-reviewed journal PLOS ONE. The study, “Assessment of a cellular host response test to risk-stratify suspected COVID-19 patients in the ...
-
Cytovale Begins Enrollment in FDA 510(k) Clinical Validation Study of IntelliSep Rapid Sepsis Test
Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune-mediated diseases, today announced the first enrollment in a clinical trial of the Cytovale system and IntelliSep test to aid in the rapid assessment of potential for sepsis in the emergency department (ED). The trial, A Clinical Validation Solving the Question of ...
-
New Study Supports Cytovale IntelliSep Test as Promising Tool to Aid in the Rapid Diagnosis of Sepsis in the Emergency Department
Cytovale, a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune mediated diseases, today announced the publication of a study in the peer-reviewed journal Critical Care Explorations (CCE) evaluating its IntelliSep test as a tool in the rapid diagnosis of sepsis in the hospital emergency department (ED). Data from the study, ...
-
Evolve BioSystems, Inc. Announces the Use of Activated B. infantis EVC001 by International Consortium to Study the Prevention of Type 1 Diabetes in Children
Evolve BioSystems, Inc. today announces that its product, activated B. infantis EVC001, will be used in one of the largest international clinical studies on preventing type 1 diabetes (T1D) in genetically predisposed children. The randomized, controlled, double-blind, multicenter trial will be conducted across eight major research centers in five European countries. The Leona M. and Harry B. ...
-
Cipla enters partnership to provide affordable oncology biosimilars to South Africa
Cipla Medpro and the wholly owned subsidiary of Cipla Limited, India have finalised a partnership agreement with the global biotechnology company mAbxience, to get oncology and respiratory-related biosimilars to South Africa. These medicine products for the treatment of cancer are on the WHO Model List of Essential Medicines. The mAbxience partnership will enable Cipla to continue its ethos of ...
By mAbxience
-
NIH statement on Asthma Awareness Month
For Asthma Awareness Month 2013, the National Institutes of Health stands with the international community to renew our dedication to improving the quality of life for the estimated 300 million people living with asthma worldwide. To most effectively manage asthma, we need to address the disproportionate impact of the disease on minorities and families at or below the poverty line. NIH is ...
-
Asthma Awareness Month 2014: NIH Continues its Commitment to Asthma Research
May is Asthma Awareness Month, and the National Institutes of Health emphasizes the scientific progress being made in asthma research, from basic science, such as how lung cells work, to clinical trials on current and future treatments for the disease. NIH-led research includes studies of environmental factors, how the body’s own defense system plays a role, and the microbiome — all ...
-
Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell ...
-
AstraZeneca to Acquire Alexion, Accelerating the Company`s Strategic and Financial Development
AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on ...
-
EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022
Patients with eosinophilic esophagitis (EoE) suffer from severe symptoms including swallowing disorders, food impaction, vomiting, and heartburn EsoCap is currently conducting a randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients in four European countries with its lead candidate ESO-101 To help raise awareness of the medical condition, EsoCap supports EUREOS and ...
By EsoCap AG
-
World Asthma Day: NIH research advances help people with asthma
Statement of Linda S. Birnbaum, Ph.D., director, National Institute of Environmental Health Sciences and National Toxicology Program; Susan B. Shurin, M.D., acting director, National Heart, Lung, and Blood Institute; and Anthony S. Fauci, M.D., director, National Institute of Allergy and Infectious Diseases Today, the National Institutes of Health joins with public health officials, health ...
-
Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines
Collaborative efforts aim to accelerate drug discovery and improve clinical success Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection Research will be focused on up to 15 novel small molecule candidates across oncology and immunology Exscientia will receive an upfront cash payment of $100 ...
By Exscientia
-
EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial
Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101 ESO-101, EsoCap’s lead product candidate, consists of a capsule with a rolled, thin mucoadhesive film, loaded with the anti-inflammatory corticosteroid, mometasone furoate In a previous trial, EsoCap’s proprietary and unique targeted application ...
By EsoCap AG
-
CARB-X is funding Spanish biotech Vaxdyn to develop a new vaccine to prevent superbug infections that cause life-threatening pneumonia and other deadly infections
CARB-X is awarding Vaxdyn, based in Seville, Spain, up to US$892,000, plus an additional $6.36 million if certain project milestones are met, to develop a new vaccine to prevent life-threatening drug-resistant infections, including pneumonia. Vaxdyn is the first Spanish biotech to be funded by CARB-X, a non-profit partnership investing $500 million in the development of innovative vaccines, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you